MorphoSys has been granted a patent for novel antibodies targeting CD38, crucial in various disorders. The patent covers methods for generating antibody variants specific to CD38, with potential applications in treating hematological malignancies like multiple myeloma. GlobalData’s report on MorphoSys gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on MorphoSys, Personalized cancer vaccines was a key innovation area identified from patents. MorphoSys's grant share as of April 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.
Generating variants of anti-cd38 antibody using specific sequences
A recently granted patent (Publication Number: US11939395B2) discloses a method for generating variants of an anti-CD38 antibody using specific VH and VL sequences. The method involves diversifying amino acid residues within CDR and framework regions of the antibody, creating a recombinant antibody library, and screening the antibodies against a CD38 antigen. The diversification can target specific regions such as CDR-3 of VL, CDR-3 of VH, CDR-1 of VL, and/or CDR-2 of VH, with the option of using trinucleotide mutagenesis technology for the diversification process.
Furthermore, the patent details the use of a phage display library for the recombinant antibodies and a screening process in a stable CHO-K1-cell line with high CD38 surface expression. This allows for the selection of antibody-phages through whole cell panning. The method outlined in the patent provides a systematic approach to generating antibody variants with potential applications in targeting CD38 antigens, showcasing innovation in antibody development techniques.
To know more about GlobalData’s detailed insights on MorphoSys, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
